Q3 2026 in numbers
According to ChemAnalyst, Lidocaine Hydrochloride USP averaged:
- USA, CFR Houston: USD 11,460.00/MT, up 8.01% quarter on quarter
- China, CFR Shanghai: USD 11,033.33/MT, up 5.78%
That is about USD 11.46/kg in the US and USD 11.03/kg in China. Compared with Q4 2025, prices are now about 12.7% higher in the US and 10.6% higher in China (computed).
How the past year unfolded
- USA: USD 10,166.67 (Q4 2025, −13.22%) → 10,080.00 (Q1 2026, −0.85%) → 10,610.00 (Q2, +5.26%) → 11,460.00 (Q3, +8.01%)
- China: USD 9,973.67 (Q4 2025, −12.66%) → 10,013.33 (Q1, +0.40%) → 10,430.00 (Q2, +4.16%) → 11,033.33 (Q3, +5.78%)
After a sharp correction in Q4 2025, driven by excess inventory and completed tenders, prices have picked up each quarter. Q3 was the strongest gain of the year in both markets.
Book a free demo to see lidocaine hydrochloride prices and the Q4 outlook: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Lidocaine%20Hydrochloride
The widening US premium
The gap between Houston and Shanghai has grown (computed):
- Q1 2026: about USD 67/MT
- Q2 2026: about USD 180/MT
- Q3 2026: about USD 427/MT
The US depends on imports from India and China. When export allocations tighten and Asia–US freight rises, US buyers feel it first and most.
USA: tight supply from Asia
- Indian and Chinese exporters held back prompt volumes in July and August, giving sellers more pricing power across the quarter.
- Higher Asia–US freight, including container costs from Mundra to Houston, raised landed replacement costs.
- Strong healthcare demand from hospitals, injectable formulators and dental use led buyers to purchase earlier and build safety stocks.
- Routine GMP inspections and environmental controls delayed some export clearances to Gulf Coast buyers.
- Few newly qualified suppliers entered the market, and regulatory qualification takes time, so established exporters kept their leverage.
ChemAnalyst’s forecast flags that geopolitical exposure of aromatic feedstocks could raise production costs and support higher replacement values in Houston.
China: imports tighten, then ease
- Origin allocations tightened early in Q3, and replacement costs rose for importers.
- European producers prioritised domestic and regional pharmaceutical customers, cutting prompt export volumes to China.
- Indian manufacturers faced higher compliance and quality-assurance costs, which firmed their offers into Shanghai.
- Shanghai inventories were drawn down to meet pharmaceutical demand. Steady hospital buying supported demand for high-purity injectable grades.
In India, supply was limited and allocations went first to regulated buyers. Higher costs for the intermediates 2,6-xylidine and chloroacetyl chloride raised conversion costs and sellers’ minimum offers.
September: the turn
The quarterly averages hide a softer end to the quarter:
- In China, spot buying fell after hospital tenders closed in August. European exporters offered discounts, and cheaper container freight and a stronger yuan lowered delivered costs.
- In the US, competitive offers from India and China increased prompt availability. With subdued spot demand and no FDA shortage alerts, buyers ran down inventories rather than buying new volume.
Europe: steady, compliance-driven
ChemAnalyst describes Europe as a market shaped by GMP requirements, quality testing and supplier qualification. Pharmaceutical manufacturers kept inventories cautious and bought in line with production schedules. European suppliers competed with imported API, and costs for intermediates, solvents and energy influenced supplier margins. Earlier in 2026, stricter environmental compliance costs and reduced Swiss export allocations lifted Q1 prices in Germany and France by 1.2%.
What this means for API buyers
- Plan Q4 tenders around September’s softness. Competitive offers and lower freight give buyers more leverage than the Q3 average suggests.
- The US premium is a cost of supply security. Qualifying alternative suppliers takes time, so a second qualified source is worth more than a small price saving.
- Watch intermediate costs. Higher 2,6-xylidine and chloroacetyl chloride costs, plus aromatic feedstock risk, set a floor under producer offers.
- Tender timing matters. In 2025 and 2026, prices weakened after hospital tenders closed. Timing purchases around tender cycles can lower average costs.
Q4 watchlist
- Export allocations from India and China, and the results of GMP inspections.
- Container freight on India–US and India–China routes.
- 2,6-xylidine and chloroacetyl chloride costs.
- Hospital and dental procurement cycles, and US inventory levels.
- FDA shortage alerts, which were absent in Q3.
Get the full picture
ChemAnalyst tracks 1,000+ commodities with weekly prices, explains why prices moved, and publishes forecasts and plant shutdown tracking, covering pharmaceutical APIs such as lidocaine hydrochloride. Its teams in Houston, Cologne and New Delhi and on the ground at 50+ ports, including Houston and Shanghai, provide first-hand trade-flow coverage.
Book a free demo to see lidocaine hydrochloride prices and the Q4 outlook: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Lidocaine%20Hydrochloride
Comments